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Abstrak 
Pengenalan 
x 
Ramai pesakit kencing manis mengalami masalah kegagalan ereksi. AI prostadiI 
atau Prostaglandin E1, pernah digunakan untuk merawat kegagalan ereksi 
melalui cara intrakavernosa dan di dapati memberikan hasil yang memuaskan. 
Walau bagaimanapun, keputusan kajian menunjukkan pesakit kencing man is 
kurang bertindakbalas dan memerlukan dos rawatan yang lebih tinggi jika 
dibandingkan dengan populasi secara umum. Sehingga ini, belum ada sebarang 
kajian yang secara khusus menilai kesan Alprostadil dikalangan pesakit kencing 
man is. 
Kajian ini menilai keberkesanan dan keselamatan rawatan Alprostadil secara 
intrakavernosa khusus bagi pesakit kencing manis yang mengalami kegagalan 
ereksi. Kami juga menilai taraf kepuasan pesakit berdasarkan indeks 
antarabangsa fungsi ereksi, iaitu suatu soal selidik yang mengemukakan 15-
soalan yang telah dipersetujui di peringkat antarabangsa dan pengumpulan 
maklumat tentang tabiat seksual pesakit sebulan selepas tamat tempoh 
rawatan. 
Kajian kami merupakan kajian label terbuka dibahagikan kepada dua fasa iaitu; 
fass peningkatan dos secara berperingkat yang dilakukan di klinik diikuti oleh 
fasa rawatan kesinambungan yang dilakukan sendiri oleh pesakit bagi tempoh 
12 minggu di rumah. Suatu temuramah di adakan 4 minggu selepas tamat 
tempoh rawatan untuk mengumpul maklumat tabiat seksual pesakit. 
30 pesakit kencing man is mengambil bahagian dalam kajian ini. Purata umur 
mereka ialah 55.8 ±8.1 tahun dan purata jangkamasa penyakit kencing manis 
ialah 11.1 ±S.4 tahun manakala purata tempoh kegagalan ereksi ialah 3.1 ±2.9 
tahun. Secara keseluruhannya, 75% peratus pesakit berjaya mencapai 
tindakbalas penuh kepada rawatan. Purata dos berkesan diawal kajian adalah 
21.5 ±12 ug. Purata dos muktamad yang digunakan adalah 26.4 ±14.2 ug. 
Purata tempoh untuk mula berkesan ialah 11.8 ±6.7 minit manakala tempoh 
kesan ereksi ialah 63 ±35.8 minit. 95% dari pesakit mencapai kepuasan 
berjimak semasa fasa kesinambungan. Indeks fungsi zakar antarabangsa 
menunjukkan keupayaan mencapai ereksi dan pengekalan tahap ereksi 
sewaktu berjimak. Sembilan orang pesakit telah menarik diri dalam masa kajian 
ini. Sebab-sebab penarikan diri termasuk; rawatan tidak berkesan (3), kesan 
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sampingan (3), penyelewengan protocol (1), gagal hadir untuk lawatan susulan 
(1) dan masalah dengan pasangan (1). Kesan samping yang paling kerap di 
hadapi ialah kesakitan ringan pada batang zakar. Sewaktu temuramah selepas 
tempoh rawatan, kekerapan berjimak dan kualiti kepuasan seksual di dapati 
tidak berubah berbanding dengan sebelum mulakan rawatan. 
Sebagai rumusan, Alprostadil secara intrakavernosa adalah berkesan dan 
selamat digunakan untuk rawatan kegagalan ereksi akibat penyakit kencing 
man is; sekiranya dos Alprostadil di sesuaikan dengan peningkatan berperingkat 
mengikut keperluan individu dan pesakit mendapat pendidikan dan latihan yang 
secukupnya dalam penggunaan rawatan injeksi. 
ABSTRACT 
Erectile dysfunction is a common complication of Diabetes Mellitus. 
Intracavernosal Alprostadil, the naturally occurring form of Prostaglandin E 1, has 
been used successfully in the treatment of erectile dysfunction. Results with 
Alprostadil have shown a poorer response, shorter duration of action and need 
for higher dosage in diabetic patients with erectile dysfunction when compared 
to the general population. No study targeted specifically to the diabetic 
population has been completed with Alprostadil so far. 
We thus set out to investigate the efficacy and safety of intracavernosal 
Alprostadil in diabetic patients with erectile dysfunction. We also assessed the 
quality of life of patients using the international index of erectile function, a 
validated 15-point questionnaire and gathered information about their sexual life 
one month after the end of treatment. 
It was an open-labelled study with a dose titration phase done at the clinic 
followed by a maintenance phase of self-injection treatment lasting 12 weeks in 
the patient's home. An interview was conducted with the patient, 4 weeks after 
the end of treatment to gather information related to the patient's sexual life. 
Thirty diabetic patients with stable partners and erectile dysfunction of at least 4 
months duration were enrolled into the study. The mean patient age was 55.8 
±8.1 years, mean duration of diabetes was 11.1 ±5.4 years and mean duration 
of erectile dysfunction was 3.1 ±2.9 years. The overall response rate was 75% 
for full and adequate erections. Mean effective dose was 21.5 ±12 ug. Mean end 
pOint dose was 26.4 ±14.2 ug. Mean latent period was 11.8 ±6.7 minutes and 
mean duration of erection was 63 ±35.B minutes. Satisfactory intercourse was 
possible in 95% of the injections during the home maintenance phase. Mean 
international index of erectile function questionnaire scores to questions 
assessing the ability to achieve and maintain erections demonstrated statistically 
Significant improvements. A total of 9 patients were withdrawn during the trial. 
Causes of withdrawal included lack of efficacy (3), adverse event (3), protocol 
X.1tl 
violation (1). failure to follow up (1) and problems with partner (1). The most 
common adverse event reported was penile pain. which was mostly mild burning 
sensation. Other adverse events recorded include injection site haematoma. 
prolonged erection. and priapism. No significant changes in frequency and 
quality of sexual activity were observed during the post study interview when 
compared with prior to initiation of therapy. 
In conclusion intracavemosal Alprostadil is efficacious and safe in the treatment 
of diabetic erectile dysfunction if the therapeutic dose of Alprostadil is defined by 
careful titration for each patient and if the patient receives proper education and 
training in the self-injection technique. 
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1 INTRODUCTION 
1.1 Physiology of Erection 
1.1.1 Haemodynamics 
Penile erection is a neurovascular event modulated by psychological factors 
and hormonal status (Krane et a/., 1989). On sexual stimulation, nerve impulses 
cause the release of neurotransmitters from the cavernous nerve terminals and 
of relaxing factors from the endothelial cells in the penis, resulting in the 
relaxation of smooth muscle in the arteries and arterioles supplying the erectile 
tissue and a several fold increase in penile blood flow (Lue et a/., 1987). At the 
same time, relaxation of the trabecular smooth muscle increases the 
compliance of the sinusoids, facilitating rapid filling and expansion of the 
sinusoidal system. The subtunical venular plexus is thus compressed between 
the trabeculae and the tunica albuginea, resulting in almost total occlusion of 
venous outflow (Fournier et al., 1987). These events trap the blood within the 
corpora cavernosa and raise the penis from a dependant position to an erect 
position, with an intracavernous pressure of approximately 100mmHg (the 
phase of full erection)( Lue et al., 1983). 
During sexual intercourse, the bulbocavernous reflex is triggered, the 
ischiocavernous muscles forcefully compress the base of the blood-filled 
corpora cavernosa and the penis becomes even harder, with the intracavernous 
pressure reaching several hundred millimetres of mercury (the phase of rigid 
erection). During this phase, the inflow and outflow of blood temporarily cease 
(Lue et al., 1983). Detumescence can be the result of a cessation of 
neurotransmitter release, the breakdown of second messengers by 
phosphodiesterases, or sympathetic discharge during ejaculation. Contraction 
of the trabecular smooth muscle reopens the venous channels, the trapped 
blood is expelled, and flaccidity returns. (8anya et al., 1989) 
1.1.2 Neurophysiology 
Autonomic and somatic nerves innervate the penis. In the pelvis, the 
sympathetic and parasympathetic nerves merge to form the cavernous nerves, 
which enter the corpora cavernosa, corpus spongiosum, and glans penis to 
regulate blood flow during erection and detumescence (Walsh et al., 1982). The 
somatic component, the pudendal nerve, is responsible for penile sensation and 
the contraction and relaxation of the extracorporeal striated muscles 
(bulbocavemous and ischiocavemous). 
There are three distinct types of erection in man, namely 'reflex', 'psychogenic' 
and 'nocturnal' (Andersson et al., 1995). Reflex erections can be induced by 
manual stimulation of the penis. This response is abolished by damage to the 
sacral spinal reflex. All normal men experience nocturnal erections. Most are 
associated with rapid eye movement sleep. It is generally assumed that the 
presence of normal nocturnal erections indicates a diagnosis of psychogenic 
impotence (Seagraves et al., 1987). Erotic stimuli induce psychogenic 
erections. The stimuli may be visual, olfactory or imaginative and the 
mechanisms are thought to involve both parasympathetic and sympathetic 
neural pathways. There appears to be a synergy between reflex and 
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psychogenic erections such that erotic visual or imaginative stimuli improve the 
response to manual stimuli and vice versa (Melman et al., 1988). 
The maintenance of the intracorporeal smooth muscle in a semicontracted state 
i.e., penile flaccidity results from three factors: intrinsic myogenic activity, 
adrenergic neurotransmission, and the endothelium-derived contracting factors 
such as prostaglandin F2a and endothelins (Saenz et al., 1989a). 
Nitric oxide released during nonadrenergic neurotransmission and from the 
endothelium is probably the principal neurotransmitter mediating penile erection 
(Saenz et al., 1989b). Within the muscle, nitric oxide activates a soluble guanyl 
cyclase, which raises the intracellular concentration of cyclic guanosine 
monophosphate (GMP). CycliC GMP in turn activates a specific protein kinase, 
which phosphorylates certain proteins and ion channels, resulting in the 
opening of potassium channels and hyperpolarisation of the muscle cell 
membrane, sequestration of intracellular calcium by the endoplasmic reticulum, 
and blocking of calcium influx by the inhibition of calcium channels (Burnett, 
1997). The consequence is a drop in cytosolic calcium concentrations and 
relaxation of the smooth muscle. During the return to the flaccid state, cyclic 
GMP is hydrolysed to GMP by phosphodiesterase type 5. Other 
phosphodiesterases are also found in the corpus cavernosum, but they do not 
have an important role in erection (Burnett, 1997). Communication among 
smooth-muscle cells takes place through gap junctions in the membrane of 
adjacent cells, which allow the passage of ions and second messengers to 
synchronize muscle activity (Christ et al., 1993). 
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1.2 Introduction to Erectile Dysfunction 
For many men, life without sex can be likened to a water colour painting that 
should possess all of the vibrant colours of life but which has been reduced to 
sterile black and white. Although regarded as a benign disorder erectile 
dysfunction (ED) has a profound effect on the quality of life of many men. ED 
impairs sexual performance, diminishes self-esteem and disrupts personal 
relationship (NIH Consensus, 1993). 
1.3 Definition 
'Erectile Dysfunction' (ED), is defined by the National Institute of Health 
Consensus Panel on Impotence as the persistent inability to attain and maintain 
an erection sufficient to perform satisfactory sexual activity (Benet et a/., 1995). 
1.4 Epidemiology 
The prevalence of ED in the community as a whole is not well documented. 
This is largely due to variability in the definition of ED and the fact that most 
studies include very selected populations. Estimates suggest, that between 20 
and 30 million men are affected in the United States alone (Benet et a/., 1995; 
Feldman et a/., 1994). Based on the data from United States, if the incidence 
were, of the order of 100/0 in the general population, there would be some 1 
million men in Malaysia suffering from ED. 
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1.5 Aetiology 
Broadly speaking, ED can be defined as being the consequence of either 
organic or inorganic (Le. psychogenic) disease. It may result from 
psychological, neurologic, hormonal, arterial, or cavemosal impairment or from 
a combination of these factors. Erectile failure is commonly due to a complex 
interaction between psychological and physical problems. In younger men 
psychological causes predominate, whilst in men aged over 50 organic causes 
are more common. A wide range of systemic diseases are associated with ED. 
1.5.1 Diabetes Mellitus 
A common complication of diabetes mellitus in men is ED. It occurs at an earlier 
age in diabetics than in the general population. In the Massachusetts Male 
Ageing Study (Feldman et al., 1994), the age adjusted prevalence of complete 
ED (no erection) was 280/0 in treated diabetics. The prevalence of complete ED 
in men attending diabetic clinics was approximately 3 times higher than that 
observed in the entire sample of men (100/0). The prevalence of ED in Diabetics 
has been reported to increase from 150/0 at age 30-34 years to 55% at age 60 
years (Smith, 1981). Characteristically, ED develops 10-15 years earlier in the 
diabetics than in non-diabetic patients (Lehman et a/., 1983). This effect is 
related both to age and the severity of the diabetes, assessed by dependence 
on treatment and presence of other diabetic complications. ED in men with 
diabetes is often associated with diabetic neuropathy and peripheral vascular 
disease. 
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1.6 Pathophysiology of Erectile Dysfunction 
Erectile dysfunction can be classified as psychogenic, organic (neurogenic, 
hormonal, arterial, cavemosal, or drug-induced), or mixed psychogenic and 
organic (Table 1.1). 
1.6.1 Diabetes Mellitus 
In most patients, the ED develops during the course of the disease, but in a 
small proportion, it may be the presenting feature. Most reports indicate that 
there is no difference in incidence between those who are treated with oral 
hypoglycaemics and those who require insulin. It has been suggested that the 
likelihood of developing ED be related to the degree of glycaemic control 
(McCulloch et al" 1980). 
The pathophysiology of ED in diabetes is multi-factorial, and the roles of 
neuropathy and arteriopathy are well recognised (Table 1.2). Diabetes can 
cause an autonomic neuropathy that may lead to ED, and it can also accelerate 
the development of atherosclerosis. Diabetes leads to abnormal endothelial and 
smooth muscle function throughout the body, and in the penis this can lead to 
ED (Whitehead et al" 1990). 
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Table 1.1 Classification and common causes of erectile dysfunction 
Category of ED Common Disorders Pathophysiology 
Performance anxiety 
Relationship problems Loss of libido, over 
Psychogenic Psychological stress inhibition, or impaired nitric oxide release 
Depression 
Hypogonadism Loss of libido and 
Hormonal Hyperprolactinemia inadequate nitric oxide 
release 
~-. 
Atherosclerosis 
Vasculogenic HypertenSion Inadequate arterial flow 
(arterial or Diabetes mellitus or impaired veno-occlusion 
cavernosal) Trauma 
Peyronie's disease 
Stroke or Alzheimer's 
disease 
Neurogenic Spinal cord injury Failure to initiate nerve 
Radical pelvic surgery impulse or interrupted 
neural transmission 
Diabetic neuropathy 
Pelvic injury 
Antihypertensive and Central depression 
antidepressant drugs 
Antiandrogens 
Decreased libido 
Drug- induced Alcohol abuse 
Cigarette smoking Alcoholic neuropathy 
Vascular insufficiency 
Old age 
Caused by other Diabetes mellitus Usually multifactorial, 
systemic diseases Chronic renal failure resulting in neural and 
and ageing vascular dysfunction 
Coronary heart disease 
(Adapted from Lue T.F., 2000) 
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Table 1.2 Possible pathophysiological factors in diabetic erectile dysfunction 
Neurogenic Autonomic Neuropathy 
Peripheral Neuropathy 
Arterial Increased risk of atherosclerosis 
Microangiopathy 
Endothelial Impaired endothelial-dependant 
smooth muscle relaxation 
Myogenic Impaired smooth muscle function 
(Adapted from Eardley et al., 1998) 
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1.6.1.1 Neural factors 
The neuropathy seen in diabetes initially affects small unmyelinated fibres 
which innervate the corpora cavernosa. In the later stages of the disease, larger 
myelinated fibres are also affected, producing the classic 'glove and stocking' 
distribution of peripheral neuropathy (Saenz at al., 1988). At a cellular level, 
there is depletion of neurotransmitters including vasoactive intestinal 
polypeptide, acetylcholine and noradrenaline in association with reduced levels 
of nitric oxide (Saenz at al., 1989b). 
1.6.1.2 Arterial factors 
Diabetes mellitus is associated both with atherosclerosis in large arteries, which 
appears more frequently and at an earlier age than in non-diabetics, and with 
microangiopathy, characterised by increased thickening of the capillary 
basement membrane (Whitehead at al., 1990). Duplex ultrasound scanning of 
the penile arteries has shown that, in impotent men, diabetes is associated with 
a smaller penile artery diameter and lower peak flow velocities following 
injection of an intracorporal vasoactive agent (Persson et al., 1989). There is a 
close correlation between diabetic ED and other manifestations of diabetic 
vascular disease, namely retinopathy, intermittent claudication and the risk of 
amputation (McCulloch et al., 1980). Any reduction in arterial flow to the penis 
will inevitably lead to ischaemic changes within the corpora. 
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1.6.1.3 Endothelial and myogenic factors 
The endothelium lining the lacunar spaces is important in controlling corporal 
smooth muscle tone, as nitric oxide, constrictor prostanoids and endothelin are 
all produced there and act directly on the smooth muscle cell. In diabetes, there 
is impaired neurogenic and endothelium-dependent smooth muscle relaxation 
to acetylcholine (Saenz et a/., 1989a). There is an augmentation of the 
contractile response to adrenergic agonists and a reduced relaxation response 
to nitric oxide upon exposure to hyperglycaemia. There is also overproduction 
of oxygen free radicals such as the superoxide anion, which can occur in 
diabetes mellitus, leading to impaired cavernosal relaxation by inactivating nitric 
oxide (Rajfer et a/., 1992). A third explanation is that hyperglycaemia leads to 
induction of the enzyme aldose reductase and to an increased production of 
sorbitol, which in turn causes an increased consumption of NADPH, an 
essential co-factor in the production of nitric oxide (Burnett, 1997). 
Advanced glycosylation end products (AGEs) have an important 
pathophysiological role in the complications of diabetes mellitus (Braunstein, 
1997). AGEs are compounds, which are formed as a result of non-enzymatic 
reaction between glucose and the amino groups of long-lived tissue proteins 
such as collagen (Sette I et al., 1997). They are found to occur in increasing 
amounts not only in association with diabetes but also with ageing. Amongst 
their various pathological effects that have been demonstrated is the ability to 
bind nitric oxide (Burnett, 1997). 
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It may be that in diabetes there is heightened contractility as well as decreased 
relaxation of the corporal smooth muscle. It is likely that the vascular and 
sinusoidal endothelium has a central role in the modulation of this process 
(Saenz et al., 1989b). 
1.7 Diagnosis of Erectile Dysfunction 
1.7.1 Assessment of Erectile Dysfunction 
When assessing the diabetic patient with ED, it is important to remember that in 
anyone individual there may be a variety of etiological processes. Erectile 
dysfunction is occasionally the presenting symptom of a variety of diseases, 
such as diabetes mellitus, coronary artery disease, hyperlipidemia, 
hypertenSion, spinal cord compreSSion, and pituitary tumour. Therefore, when a 
patient presents with ED, a thorough history (medical, sexual, and 
Psychosocial) should be taken, the patient should undergo physical 
examination, and appropriate laboratory tests aimed at detecting these 
diseases should be performed. Erectile failure due to diabetes mellitus tends to 
have a gradual onset, whereas a sudden loss of erections suggests a 
psychosexual problem. A detailed psychosocial history may reveal deep-seated 
psychological problems or relationship conflicts that can be successfully treated 
only by mental health professionals. All drugs being taken and the duration of 
their treatment should be recorded. The physical examination should include 
evaluation of the breasts, hair distribution, penis, and testes; palpation of the 
femoral and pedal pulses; and testing of genital and perineal sensation. 
Particular attention should be paid to any signs of diabetic complications. Any 
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general physical disability must be noted including any problems with impaired 
mobility or manual dexterity, poor cognitive function or problems with vision. 
Any of this may not only impair sexual function but also be relevant to the 
planning of treatment. Recommended laboratory tests include urine analyses, a 
complete blood count, and measurements of serum glucose, creatinine, 
cholesterol, triglycerides, and testosterone while the patient is fasting. If the 
man's serum testosterone concentration is low, serum free (or bioavailable) 
testosterone, prolactin, and luteinizing hormone should be measured. 
The physician should then assess the findings, inquire about the goals and 
preferences of the man (and his partner), discuss further diagnostic tests (Table 
1.3) and therapeutic options (Table 1.4), and provide information on sexual 
physiology and pathophysiology so that the man's participation and that of his 
partner in the decision-making process will be well informed. 
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Table1.3 Specialised urologic and radiologic tests. 
Test Indications 
Combined penile injection of a Assess penile vascular function 
vasodilator and sexual stimulation Therapeutic test in men who 
choose intracavernous therapy 
Duplex (color) ultrasonography Assess vascular function and 
evaluate for Peyronie's disease 
Cavernosography Young men with traumatised or 
congenital venous leakage 
Penile arteriography Young men with traumatised 
arterial insufficiency 
Nocturnal penile monitoring Differentiate psychogenic from 
organic erectile dysfunction 
(Adapted from Lue T.F., 2000) 
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Table 1.4 Treatment options 
Treatment Advantages 
Non invasive 
Psychosexual therapy Partner involved 
Curative 
Oral sildenafil 
Transurethral 
Alprostadil 
Intracavernous 
Alprostadil 
Vacuum constriction 
device 
Surgical prosthesis 
Vascular surgery 
Oral dose 
Effective 
Local therapy 
Few systemic side 
effects 
Highly effective 
Few systemic side 
effects 
Least expensive 
No systemic side 
effects 
Highly effective 
Curative 
(Adapted from Lue T.F., 2000) 
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Disadvantages 
Time consuming 
Patient resistance 
Cardiovascular disease 
a contraindication in 
some men 
1hour wait 
Moderately effective 
Requires office training 
Causes penile pain 
Requires injection 
High dropout rate 
Can cause priapism or 
fibrosis 
Causes penile pain 
Unnatural erection 
Causes petechiae 
Causes numbness 
Trapped ejaculation 
Unnatural erection 
Infection 
Requires replacement in 
5-10 years 
Requires anaesthesia 
and surgery 
Poor results in older 
men with generalised 
disease 
Requires anaesthesia 
and surgery 
Some men may benefit from referral for further testing and treatment. The 
indications for referral to a specialist include complex gonadal or other 
endocrine disorders, a neurologic deficit suggestive of brain or spinal cord 
disease, deep-seated psychological or psychiatric problems, Peyronie's 
disease, post-traumatic or primary ED, and active cardiovascular disease, 
especially if the man wishes to take sildenafil. If primary hypogonadism is 
detected, androgen therapy is the treatment of choice. This approach to the 
diagnosis and treatment of ED is tailored to the individual man's health status 
and goals. 
1.7.2 Scales for Erectile Dysfunction 
ED scales are helpful to standardise the severity of patients' symptoms and to 
provide an objective measure of the effects of the various treatments. In 
general, these involve patients self-reporting on their sexual function by a series 
of questionnaires but it is essential that these be adequately validated and 
relatively easy to administer. Various such questionnaires have been described. 
A good example is the International Index of Erectile Function (liEF) (Rosen et 
al., 1997). This scale is based on a 15-item questionnaire, identifies five 
important domains, namely erectile function (six questions), orgasmic function 
(two questions), sexual desire (two questions), intercourse satisfaction (three 
questions), and overall satisfaction (two questions). This scale has been 
validated in studies of 351 men. This scale also has high sensitivity and 
specificity in monitoring effects of treatment. Its shortcomings are that it 
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concentrates only on erectile function and not on the other components of 
sexual function and that there is limited assessment of the partner. 
1.8 Drug Therapy for ED 
1.8.1 Androgen Replacement Therapy 
In men with hypogonadism, oral testosterone preparations are less effective 
than intramuscular and transdermal testosterone preparations (Morales et al., 
1994; Arver et al., 1996) and may be hepatotoxic (causing cholestasis, hepatitis, 
and benign or malignant tumors). Testosterone cypionate and testosterone 
enanthate are often used for replacement therapy; the usual dosage is 200 mg 
intramuscularly every two to three weeks. Their chief drawback is their roller-
coaster effect: they have high activity the first week after injection, with a 
decrease thereafter (Morales et al., 1994). Transdermal testosterone 
preparations are now available. Daily application of these preparations raises 
serum testosterone concentrations to within the normal range in over 90 percent 
of men (Arver et al., 1996). The most common adverse effects are skin irritation 
and contact dermatitis. Because it stimulates growth of the prostate, androgen 
therapy is contraindicated in men with prostate cancer or obstruction of the 
bladder neck caused by prostate hypertrophy. In men receiving long-term 
testosterone therapy, the haematocrit and serum testosterone, lipids, and 
prostate-specific antigen should be measured every six months (Cooper et al., 
1996). 
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1.8.2 Oral therapy 
Sildenafil 
Sildenafil is a selective inhibitor of phosphodiesterase type 5, which inactivates 
cyclic GMP. When sexual stimulation releases nitric oxide into the penile 
smooth muscle, inhibition of phosphodiesterase type 5 by sildenafil causes a 
marked elevation of cyclic GMP concentrations in the penis, resulting in 
increased smooth-muscle relaxation and better erection (Beavo, 1995). 
Sildenafil has no effect on the penis in the absence of sexual stimulation, when 
the concentrations of nitric oxide and cyclic GMP are low (8001ell et a/., 1996). 
In clinical studies, the number of erections and the rates of penile rigidity, 
orgasmic function, and overall sexual satisfaction was significantly higher with 
sildenafil than with placebo (Goldstein et a/., 1998a). Most adverse events were 
mild to moderate and self-limited in duration (Goldstein et al., 1998a). Adverse 
events include headache, flushing, dyspepsia, nasal congestion, and abnormal 
vision (described as a mild and transient colour tinge or increased sensitivity to 
light). The visual effect is probably related to inhibition of phosphodiesterase 
type 6 in the retina. No chronic visual impairment has been reported. Adverse 
cardiovascular events (nasal congestion, headache, and flushing) were mild 
and transient in the majority of men (Morales et al.,1998). However; because 
most of the studies excluded men taking nitrates and those with concomitant 
medical conditions, the incidence of serious cardiovascular events could be 
expected to be higher in the general population. Cardiovascular status should 
be carefully assessed before treatment. The combination of nitrates and 
sildenafil has resulted in severe hypotension and deaths (Cheitlin et a/., 1999). 
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Therefore, nitrate therapy is an absolute contraindication to sildenafil therapy. In 
response to the concern of physicians, the American Heart Association has 
published a guideline for sildenafil therapy (Cheitfin et al., 1999). Sildenafil is 
absorbed well, and the plasma concentrations are maximal within 30 to 120 
minutes (mean, 60). It is eliminated predominantly by hepatic metabolism, and 
the terminal half-life is about four hours. The recommended starting dose is 50 
mg taken one hour before sexual activity. The maximal recommended 
frequency is once per day. On the basis of effectiveness and side effects, the 
dose may be increased to 100 mg or decreased to 25 mg (Goldstein et a/., 
1998a; Marc et a/., 1999). 
Yohimbine 
Yohimbine is an <l2-adrenergic receptor antagonist. It presumably acts at the 
adrenergic receptors in brain centres associated with libido and penile erection. 
A meta-analysis of studies found that yohimbine was better than placebo for all 
types of erectile dysfunction combined. And its effect was most noticeable with 
respect to non-organic ED (Ernst et a/., 1998). The most frequently reported 
side effects are palpitation, fine tremor, elevation of blood pressure, and 
anxiety. 
Phentolamine 
Oral phentolamine has been reported to improve erectile function (Gwinup, 
1988, Goldstein, 1998b). Side effects include headache, facial flushing, and 
nasal congestion. 
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Apomorphine 
Apomorphine is a potent emetic that acts on central dopaminergic (D 1 or D2) 
receptors. When injected subcutaneously, it induces erections but the side 
effects, notably nausea, seriously limit its clinical usefulness. A sublingual 
formulation of apomorphine is undergoing clinical trials (Padma et al., 1998). 
Trazodone 
Trazodone is a serotonin antagonist and reuptake inhibitor, used as a sedative 
and antidepressant, which causes priapism in rare cases. Its effect on erection 
is thought to be the result of serotonergic and a.-adrenolytic activity. Trazodone 
alone or in combination with yohimbine has been reported to improve erectile 
function in some men (Lance et al., 1995; Montorsi et al., 1994). 
1.8.3 Transurethral Therapy 
Prostaglandin E1 is an endogenous unsaturated 20-carbon fatty-acid derivative 
of arachidonic acid, and Alprostadil is a more stable, synthetic form of 
prostaglandin E1. Transurethral AI prostadil was effective in 43 percent of men 
with erectile dysfunction from various organic causes (Padma et al., 1997; 
Wolfson et al., 1993). The advantages include local application, minimal 
systemic effects, and the rarity of drug interactions. The major drawbacks are 
moderate-to-severe penile pain, a low response rate, and inconsistent efficacy 
(Wertman et al., 1997). 
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The first application (usually a 500 J,1g dose) should be undertaken in the 
physician's office because of the potential complications of urethral bleeding, 
vasovagal reflex, hypotension, and priapism. Depending on the erectile 
response, the man can then be instructed to increase or decrease the dose (up 
to 1000 f.lQ or down to 250 f.lg) (Padma et al., 1997). 
1.8.4 Intracavernous Therapy 
The introduction of intracorporal injection therapy in the early 1980s 
revolutionised the treatment of ED as it was the first means of providing safe 
and effective treatment for men with erectile difficulties (Brindley, 1983; Virag, 
1982). The next significant advance occurred in 1986 when the first results of 
injecting prostaglandin E1 (PGE1) into the penis were reported. It soon became 
clear that the use of PGE1 led to improved efficacy and was associated with a 
reduction in side effects (Stack I et al., 1988). 
These compounds produce an erection by their action upon the penile smooth 
muscle. Although the compounds used in intracorporal injection may exert 
effects on smooth muscle throughout the body, the doses required to produce 
erections are so small that they rarely cause systemic side effects when 
injected into the penis. The method of administration directly into the penis 
allows good local concentrations to be achieved with small doses, with minimal 
spill into the general circulation (Virag, 1982). 
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The most commonly used intracavemous drugs are alprostadil and a 
combination of papaverine, phentolamine, and alprostadil (trimix) (Gupta et al., 
1997). 
Papaverine 
Papaverine is a phosphodiesterase inhibitor that increases cyclic AMP and 
cyclic GMP concentrations in penile erectile tissue (Stief et a/., 1988). The usual 
dose ranges from 15 to 60 mg. It is highly effective in men with psychogenic 
and neurogenic erectile dysfunction, but it is less effective in men with 
vasculogenic erectile dysfunction (Virag, 1982). Its advantages include low cost 
and stability at room temperature. Major disadvantages are priapism, corporal 
fibrosis, and occasional increases in serum aminotransferase concentrations 
(Stief et al., 1988). 
Phentolamine 
Phentolamine is a competitive a-adrenergic receptor antagonist. Phentolamine 
produces erections when combined with papaverine (Stief et al., 1988). Most 
urologists prescribe a combination of 30 mg of papaverine and 0.5 to 1 mg of 
phentolamine, and the usual dose ranges from 0.1 to 1 ml. The side effects of 
phentolamine include hypotension and reflex tachycardia. 
Vasoactive Intestinal Polypeptide 
Vasoactive intestinal polypeptide is a potent smooth muscle relaxant which 
when combined with phentolamine, produced erections sufficient for sexual 
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intercourse (Dinsmore et al., 1998). Common side effects include transient 
facial flushing, bruising, pain at the injection site, and truncal flushing. 
AI prostadiI 
Prostaglandin E1 (PGE1) is now the most commonly used single agent for 
intracorporal injections. It has achieved this dominance because of its efficacy 
and safety, which are superior to all other single agents (Porst, 1996). It acts 
primarily via specific receptors on the surface of the smooth muscle cell to 
stimulate the enzyme adenylate cyclase (Linet et al., 1994). This enzyme 
converts ATP to cyclic AMP (cAMP) and therefore injection of PGE1 causes a 
rise in intracellular cAMP, which in tum results in a fall in intracellular 'calcium 
and smooth muscle relaxation. PGE1 may also reduce the noradrenaline 
released from presynaptic noradrenergic nerve terminals, with the anticipated 
synergistic effects (Stackl et aI., 1988). 
Three formulations of alprostadil have been used for intracavemous injection: 
Prostin VR (Pharmacia & Upjohn), a paediatric formulation; Caverject 
(Pharmacia & Upjohn), a lyophilized powder; and Edex (Schwarz Pharma), 
Which contains alprostadil in complex with a-cyclodextrin. 
Alprostadil is the only intracavernous drug approved in the United States. Its 
efficacy is superior to that of papaverine and the combination of papaverine and 
phentolamine; it results in erections in more than 70 percent of men (Stack I et 
al., 1988; Lee et al., 1989). 
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In addition, Alprostadil is associated with a relatively low incidence of priapism 
and fibrosis (Porst, 1996). 
The usual dose ranges from 5 to 20 Ilg. The most frequent side effect is painful 
erections (Porst, 1996). The hyperalgesic effect is more prominent in men with 
partial nerve injury, such as those with diabetic neuropathy. 
Although the response rate is high, in long-term studies 38 to 80 percent of men 
ceased therapy (Weiss et al., 1994; Gupta et al., 1997). There are several 
published reports on the use of Alprostadil in diabetic patients. The success 
was lower in patients over 60 years of age and in patients with duration of 
diabetes longer than 10 years (Ishii et al., 1986; Stack I et al., 1988; Porst, 
1996). No significant differences were found between the diabetics and non-
diabetics in terms of satisfaction with the injection technique and in adverse 
reactions. The diabetics had a significantly shorter duration of erection (Linet et 
al., 1994; Stack I et al., 1988). Some men alternate injection therapy with 
sildenafil or transurethral alprostadil, preferring injection when an erection of 
longer duration is desired. 
1.8.5 Transdermal Medications 
Nitroglycerin cream or paste, alprostadil cream, and a cream containing 
aminophyline, isosorbide dinitrate, and co-dergocrine mesylate have been used 
in pilot studies in men with erectile dysfunction; the results have been mixed 
(Gomaa et al., 1996). 
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1.9 Rationale for the study 
A new formulation of PGE1, namely Alprostadil Sterile Powder 
[s. Po. ,CAVERJECT®] has been developed and investigated. Many clinical 
studies have been completed to evaluate the effectiveness and safety of 
Alprostadil in the treatment of ED (Stackl et a/., 1988; Lee et a/., 1989; Linet et 
al., 1994; Porst, 1996). A total of 1,712 men aged 20 to 79 years (mean, 54.9 
years) with ED of vasculogenic, neurogenic, psychogenic, mixed, or unknown 
aetiology have received intracavemosal treatment with Alprostadil in these 
studies and 280 patients were injected with placebo. Based on the results of 
these trials, it was concluded that if the therapeutic dose of Alprostadil is 
defined by careful titration for each patient and if the patient receives proper 
education and training in the self-injection technique, Alprostadil is an effective 
and safe treatment for ED. 
Patients with diabetes mellitus required somewhat higher doses of Alprostadil to 
achieve a response and a lesser number of diabetic patients responded to 
Alprostadil than patients without diabetes (Burgess et a/., 1990). The mean 
optimum dose for diabetic patients was 21.5 J.1g while the mean optimum dose 
for non-diabetic patients was 17.4 J.lg. Response rates were 76% (115/152) for 
diabetic patients and 870/0 (598/684) for non-diabetic patients. 
No study targeted specificaUy to the diabetic population has been completed 
with AlprostadH so far. The purpose of this study was to gain experience with 
Alprostadil in Malaysian diabetic patients with ED. Information was gathered 
about the sex life of the patient one month after the end of treatment and an 
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